516 related articles for article (PubMed ID: 18954396)
1. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days.
Albanyan AM; Harrison P; Murphy MF
Transfusion; 2009 Jan; 49(1):108-17. PubMed ID: 18954396
[TBL] [Abstract][Full Text] [Related]
2. Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage.
Skripchenko A; Kurtz J; Moroff G; Wagner SJ
Transfusion; 2008 Jul; 48(7):1469-77. PubMed ID: 18482181
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of platelet activation and cytokine release during storage of platelet concentrates processed from buffy coats either manually or by the automated OrbiSac system.
Vetlesen A; Mirlashari MR; Ezligini F; Kjeldsen-Kragh J
Transfusion; 2007 Jan; 47(1):126-32. PubMed ID: 17207241
[TBL] [Abstract][Full Text] [Related]
4. Measurement of phosphatidylserine exposure during storage of platelet concentrates using the novel probe lactadherin: a comparison study with annexin V.
Albanyan AM; Murphy MF; Rasmussen JT; Heegaard CW; Harrison P
Transfusion; 2009 Jan; 49(1):99-107. PubMed ID: 18954406
[TBL] [Abstract][Full Text] [Related]
5. The quality of platelet concentrates produced by COBE Spectra and Trima Accel cell separators during storage for 7 days as assessed by in vitro methods.
Tynngård N; Lindahl TL; Trinks M; Studer M; Berlin G
Transfusion; 2008 Apr; 48(4):715-22. PubMed ID: 18208416
[TBL] [Abstract][Full Text] [Related]
6. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates.
Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
Transfusion; 2008 Oct; 48(10):2114-21. PubMed ID: 18647365
[TBL] [Abstract][Full Text] [Related]
7. Storage of buffy-coat-derived platelets in additive solutions at 4 degrees C and 22 degrees C: flow cytometry analysis of platelet glycoprotein expression.
Sandgren P; Hansson M; Gulliksson H; Shanwell A
Vox Sang; 2007 Jul; 93(1):27-36. PubMed ID: 17547562
[TBL] [Abstract][Full Text] [Related]
8. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production.
Levin E; Culibrk B; Gyöngyössy-Issa MI; Weiss S; Scammell K; LeFresne W; Jenkins C; Devine DV
Transfusion; 2008 Nov; 48(11):2331-7. PubMed ID: 18631169
[TBL] [Abstract][Full Text] [Related]
9. Storage of platelet concentrates from pooled buffy coats made of fresh and overnight-stored whole blood processed on the novel Atreus 2C+ system: in vitro study.
Sandgren P; Callaert M; Shanwell A; Gulliksson H
Transfusion; 2008 Apr; 48(4):688-96. PubMed ID: 18194379
[TBL] [Abstract][Full Text] [Related]
10. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
Picker SM; Steisel A; Gathof BS
Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
[TBL] [Abstract][Full Text] [Related]
11. In vitro function of buffy coat-derived platelet concentrates stored for 9 days in CompoSol, PASII or 100% plasma in three different storage bags.
Cardigan R; Sutherland J; Garwood M; Bashir S; Turner C; Smith K; Hancock V; Wiltshire M; Pergande C; Williamson LM
Vox Sang; 2008 Feb; 94(2):103-12. PubMed ID: 18034786
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.
Apelseth TØ; Bruserud Ø; Wentzel-Larsen T; Bakken AM; Bjørsvik S; Hervig T
Transfusion; 2007 Apr; 47(4):653-65. PubMed ID: 17381624
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic analysis of platelets during storage: a comparison between apheresis- and buffy coat-derived platelet concentrates.
Paglia G; Sigurjónsson ÓE; Rolfsson Ó; Hansen MB; Brynjólfsson S; Gudmundsson S; Palsson BO
Transfusion; 2015 Feb; 55(2):301-13. PubMed ID: 25156572
[TBL] [Abstract][Full Text] [Related]
14. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days.
Shanwell A; Diedrich B; Falker C; Jansson B; Sandgren P; Sundkvist L; Svensson L; Vesterinen M; Gulliksson H
Transfusion; 2006 Jun; 46(6):973-9. PubMed ID: 16734814
[TBL] [Abstract][Full Text] [Related]
15. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
Lozano M; Galan A; Mazzara R; Corash L; Escolar G
Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
[TBL] [Abstract][Full Text] [Related]
16. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
17. Frequently used plateletpheresis techniques result in variable target yields and platelet recruitment of donors.
Strasser EF; Schuster M; Egler K; Bauer J; Weisbach V; Ringwald J; Zimmermann R; Zingsem J; Eckstein R
Transfusion; 2005 May; 45(5):788-97. PubMed ID: 15847670
[TBL] [Abstract][Full Text] [Related]
18. Soluble glycoprotein V as a quality marker of platelet concentrates stressed by transportation.
Javela K; Eronen J; Sarna S; Kekomäki R
Transfusion; 2005 Sep; 45(9):1504-11. PubMed ID: 16131384
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the extent of platelet activation in platelet concentrates and in vitro and in vivo parameters.
Dijkstra-Tiekstra MJ; Pietersz RN; Huijgens PC
Vox Sang; 2004 Nov; 87(4):257-63. PubMed ID: 15585021
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
